FN Media Group Presents USA News Group News Commentary
Vancouver, BC –November 9, 2021 – USA News Group – After the launch of US President Joe Biden’s pushing of mandatory vaccination/testing in the workplace, new problems have arisen, such as expensive testing costs, and rampant supply shortages. On top of that, accuracy issues have also plagued the cause, as a series of false positive test results demonstrated on the popular TV show The View recently, and highlighted flaws in current Covid-19 testing protocols. False positives are becoming increasingly likely, with false positive rates as high as 16.7%. Now new options for businesses and their employees are coming from companies such as Bloom Health Partners Inc. (CSE:BLMH), Qiagen N.V. (NYSE:QGEN), BioNTech SE (NASDAQ: BNTX), Novavax, Inc. (NASDAQ: NVAX), INOVIO (NASDAQ:INO).
Now with the USA’s pending mandates coming from Occupational Health and Safety Administration (OSHA) and the Biden Administration, organizations with more than 100 employees will be required to either have employees vaccinated or test regularly.
In the wake of this shift, global healthcare security, diagnostic treating and occupational health-tech providers Bloom Health Partners Inc. (CSE:BLMH) have steadily gained new clients with their scalable, integrated platform that manages health and safety data in the workplace. The company is coming off of a recent rebranding from its previous name, Maitri Health.
“Going to market with our new brand marks an exciting milestone for our business,” said Andrew Morton, CEO of Bloom. “We’ve worked hard over the past few months to align health services, products and strategy on a single platform.”
After the acquisition of Round Hill Health Partners LLC on July 14, 2021, Bloom has since combined its network of labs and clinical expertise with a cloud software platform strategy.
Now operating under one brand, Bloom is defining ‘Occupational Health Tech’ as a complete solution for organizations to run safely today and more efficiently in the future.
Bloom’s clients include film and tv productions, Fortune 500, government, sports and entertainment, and the company has reported experiencing tremendous demand for testing across the US and Canada.
“We’ve created a unified brand message for our clients that represents a focus on intelligent health products and services,” added Morton. “Bloom is defining a new category: Occupational Health-Tech. Our platform combines technology, laboratories, advisory services and clinical expertise. We’re successfully getting clients through the pandemic and helping them structure health strategies that will continue through the years to come.”
As an end-to-end provider, Bloom has onsite clinical services, best in class laboratories and advisory services integrated with a data driven digital platform.
Abbott Laboratories has witnessed similar trends, especially for its BinaxNOW tests, which spokesperson for the company, John Koval, claims are seeing “unprecedented demand”.
“Today, there are tens of millions of BinaxNOW tests in various settings and supply chains,” Koval said in an email. “We’re working with our customers to ensure tests get to where they’re most needed and we’re ramping back up, as we did last year… There will be some supply constraints over the coming weeks as increased capacity comes online.”
Unfortunately for Abbott, in mid October, issues regarding false-positives and accuracy led to a recall of two lab test kits, according to the FDA.
Earlier this year the FDA granted an Emergency Use Application (EUA) to Becton, Dickinson and Company (‘BD’) for its BD VeritorTM At-Home Covid-19 Test—the first at-home Covid-19 rapid antigen test to use computer vision technology in a smartphone to interpret and provide digital display of testing results.
“The rise in COVID-19 cases from the Delta variant has increased the demand for at-home testing, and the BD Veritor™ At-Home COVID-19 Test is an easy-to-use test with definitive digital results that is ideal for use in the home,” said Dave Hickey, president of Life Sciences for BD. “New mandates from governments and businesses are specifying the need for periodic testing for those who cannot or chose not to be vaccinated, and this new test may help businesses, governments or schools fulfill those requirements.”
The BD Veritor™ At-Home COVID-19 Test is designed to be easily performed at home by people 14 years of age or older, using Scanwell Health’s app to provide clear digital results in 15 minutes.
Another home test from German genetic testing specialists Qiagen N.V. (NYSE:QGEN) is seeking to capitalize on the detection of even more everyday infections. So far, Qiagen’s net profit of $250m in the first six months of 2021 has been almost double that of the same period in 2020, when Covid-19 testing was still limited.
“[Demand for Covid-19 tests] completely changed the paradigm for a company like ours,” Thierry Bernard, chief executive, told the Financial Times. The shift exploded the value of Qiagen, which saw multibillion takeover attempts from majors in the industry last year.
In other Covid-19 Related news and happenings:
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, announced that the U.S. Food and Drug Administration (FDA) provided authorization to proceed for INOVIO’s INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S. The FDA has lifted the partial clinical hold following the FDA’s review of additional non-clinical, clinical, and device information provided by INOVIO.
Dr. J. Joseph Kim, INOVIO’s President and CEO, said, “I want to recognize and express my appreciation to my INOVIO colleagues for their hard work throughout this process. We are pleased to have the opportunity for U.S. clinical trial participants to potentially contribute to the enrollment in our INNOVATE Phase 3 segment. Today’s U.S. announcement builds on our intensive global efforts in India, Brazil, Philippines, Mexico, Colombia, and Thailand where we have received authorizations to date.”
Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the completion of its rolling submission to the World Health Organization (WHO) for emergency use listing (EUL) of NVX-CoV2373, its COVID-19 vaccine candidate.
“Today’s submission reflects our continued focus on accelerating access and equitable distribution as we work to bring our vaccine to people in need around the globe,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “We continue to work with urgency to deliver our COVID-19 vaccine, built on a proven, well-understood vaccine platform, because no one is safe until everyone is safe.”
Pfizer Inc. and BioNTech SE (NASDAQ: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age (also referred to as 5 to <12 years). For this age group, the vaccine is to be administered in a two-dose regimen of 10-µg doses given 21 days apart. The 10-µg dose level was carefully selected based on safety, tolerability and immunogenicity data. This is the first COVID-19 vaccine authorized in the U.S. for individuals 5 through 11 years of age.
“This is a day so many parents, eager to protect their young children from this virus, have been waiting for,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Over 6 million children in the U.S. have been diagnosed with COVID-19 since the start of this pandemic, and a high number of young people continue to be infected every week. With this FDA authorization, we have achieved another key marker in our ongoing effort to help protect families and communities, and to get this disease under control.”
Read more here: https://equity-insider.com/2020/11/04/a-healthcare-company-with-a-technological-advantage/
Article Source:
USA News Group
http://USAnewsgroup.com
info@usanewsgroup.com
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Bloom Health Partners Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Bloom Health Partners Inc. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Bloom Health Partners Inc. and reserves the right to buy and sell, and will buy and sell shares of Bloom Health Partners Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:
editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
SOURCE USA News Group
The post Rising Test Accuracy Standards Needed as On-Site Demand for Covid-19 Testing Increases appeared first on Financial News Media.
